Patent: 9,823,256
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Summary for Patent: 9,823,256
Title: | CXCR1 as a predictor of response to treatment with epidermal growth factor receptor therapeutic |
Abstract: | There is provided a molecular marker CXCR1 for predicting response and survival in subjects afflicted with cancer who would benefit from treatment with and Epidermal Growth Factor Receptor (EGFR) targeted therapeutic. |
Inventor(s): | Waugh; David John James (Bangor, GB), Wilson; Richard (Belfast, GB), Oladipo; Olabode (Belfast, GB) |
Assignee: | The Queen\'s University of Belfast (Belfast, GB) |
Application Number: | 14/113,783 |
Patent Claims: | see list of patent claims |
Details for Patent 9,823,256
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 02/12/2004 | See Plans and Pricing | 2031-04-26 |
Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 03/28/2007 | See Plans and Pricing | 2031-04-26 |
Amgen, Inc. | VECTIBIX | panitumumab | Injection | 125147 | 09/27/2006 | See Plans and Pricing | 2031-04-26 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |